Skip to main content
Figure 5 | BMC Clinical Pharmacology

Figure 5

From: No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

Figure 5

Time course of the median cardiac output (CO) estimated by transthoracic impedance cardiography throughout the main profiling days. Regimen A: baseline Day 1 (NO treatment), Day 11 (R alone: roflumilast 500 μg once daily) and Day 18 (RF: roflumilast 500 μg once daily and formoterol 24 μg twice daily). Regimen B: baseline Day 1 (NO treatment), Day 8 (F alone: formoterol 24 μg twice daily) and Day 18 (FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily).

Back to article page

BMC Clinical Pharmacology

ISSN: 1472-6904